Gemfibrozil
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Gemfibrozil: From Hypertriglyceridemia to Rheumatoid Arthritis
One-Sentence Summary
Gemfibrozil is a lipid-lowering drug (a PPAR-alpha agonist), originally used to treat hypertriglyceridemia. The TxGNN model predicts it may be effective for rheumatoid arthritis, but so far only 4 publications (mostly animal or indirect studies) support this direction, with no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertriglyceridemia |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, gemfibrozil is a fibrate that activates PPAR-alpha, and its efficacy in lowering triglycerides is established.
PPAR agonism also has anti-inflammatory and immunomodulatory effects, such as reduced pro-inflammatory cytokines and modulation of T-cell responses. Because rheumatoid arthritis is a chronic immune-driven inflammatory disease, this offers a plausible, though indirect, mechanistic link. The supporting work comes from a pan-PPAR agonist (bezafibrate) in an experimental RA model and from a rat arthritis study combining gemfibrozil with a reduced steroid dose. Neither is human clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41207105 | 2026 | Preclinical (animal) | International Immunopharmacology | Bezafibrate, a pan-PPAR agonist, attenuated experimental RA through PPAR-dependent modulation of inflammatory pathways, with emphasis on PPAR-γ activity. This is a related drug, not gemfibrozil. |
| 30074417 | 2019 | Preclinical (rat model) | Modern Rheumatology | Gemfibrozil combined with a reduced prednisolone dose gave a management picture similar to the full steroid dose in rat adjuvant-induced arthritis. |
| 20083653 | 2010 | Preclinical (mechanistic) | Journal of Immunology | Myelin basic protein priming reduced Foxp3 expression in T cells via nitric oxide. Only indirectly relevant to autoimmunity. |
| 18039017 | 2007 | Review | American Journal of Clinical Dermatology | Review of palmar erythema as a clinical sign. Low relevance. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08467P | BROZIL CAPSULE 300 mg | Capsule | Not listed in the available data |
| SIN04902P | IPOLIPID CAPSULE 300 mg | Capsule | Not listed in the available data |
| SIN09167P | LIPISTOROL CAPSULE 300 mg | Capsule | Not listed in the available data |
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): liver disease, gallbladder disease, cholelithiasis (including cholecystolithiasis and choledocholithiasis), primary biliary cholangitis, impaired renal function, thrombocytopenia, anemia (including macrocytic anemia), leukopenia, Reynolds syndrome.
- Drug Interactions: 100 interactions were found in total. Major-level interactions include:
- Statins: rosuvastatin, simvastatin
- Antidiabetics: pioglitazone, repaglinide
- Antidiarrhoeals: loperamide, eluxadoline
Moderate-level interactions include insulins (aspart, degludec, detemir, glargine, glulisine, human), nateglinide, rosiglitazone, chlorpropamide, tolazamide, chenodeoxycholic acid and rifaximin.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but the evidence is only preclinical and indirect (L4). There are no clinical trials in rheumatoid arthritis, and the animal data involve either a related drug or a combination with steroids. In addition, patients with RA often take multiple medications, so the drug interaction profile and the liver, kidney and blood-count-related cautions need attention.
To proceed, the following is needed:
- Detailed mechanism of action data, especially gemfibrozil's effects on inflammatory pathways relevant to RA
- Further preclinical studies using gemfibrozil alone in RA models
- Package insert warnings and contraindications from the Singapore regulator (HSA), so safety screening can begin
- A review of drug interactions with common RA treatments
- A well-designed early-phase clinical study if preclinical results are supportive
Note on other predictions: Among the other predicted indications, HIV infectious disease (L2) and hypoalphalipoproteinemia (L2) have more supporting evidence than rheumatoid arthritis. However, these are largely extensions of gemfibrozil's existing lipid-lowering use (managing protease inhibitor-associated hypertriglyceridemia, and raising low HDL cholesterol) rather than true repurposing. They may be worth considering as research questions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.